Indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non–ST-segment elevation myocardial infarction or documented silent ischemia due to atherosclerotic lesions in the native coronary arteries with a reference vessel diameter of 2.25 to 4 mm and a lesion length of ≤ 36 mm
Boston Scientific Corporation
Synergy Bioabsorbable Polymer Drug-Eluting Stent System
Everolimus
Platinum chromium
Bioabsorbable PLGA
0.014
5
2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5
8, 12, 16, 20, 24, 28, 32, 38
144
Coronary
Boston Scientific Corporation
Synergy XD Everolimus-Eluting Platinum Chromium Coronary Stent System
Everolimus
Platinum chromium
Bioabsorbable PLGA
0.014
5
2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5
8, 12, 16, 20, 24, 28, 32, 38, 48
144
Coronary
Advertisement
Advertisement
We value keeping the Device Guide up to date.
If you want to add or update your company’s device listings, please let us know!